Quirk Jennifer C, Nisenbaum Eric S
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285-0510, USA.
CNS Drug Rev. 2002 Fall;8(3):255-82. doi: 10.1111/j.1527-3458.2002.tb00228.x.
LY404187 is a selective, potent and centrally active positive allosteric modulator of AMPA receptors. LY404187 preferentially acts at recombinant human homomeric GluR2 and GluR4 versus GluR1 and GluR3 AMPA receptors. In addition, LY404187 potentiates the flip splice variant of these AMPA receptors to a greater degree than the flop splice variant. In both recombinant and native AMPA receptors, potentiation by LY404187 displays a unique time-dependent growth that appears to involve a suppression of the desensitization process of these ion channels. LY404187 has been shown to enhance glutamatergic synaptic transmission both in vitro and in vivo. This augmentation of synaptic activity is due to the direct potentiation of AMPA receptor function, as well as an indirect recruitment of voltage-dependent NMDA receptor activity. Enhanced calcium influx through NMDA receptors is known to be a critical step in initiating long-term modifications in synaptic function (e.g., long-term potentiation, LTP). These modifications in synaptic function may be substrates for certain forms of memory encoding. Consistent with a recruitment of NMDA receptor activity, LY404187 has been shown to enhance performance in animal models of cognitive function requiring different mnemonic processes. These data suggest that AMPA receptor potentiators may be therapeutically beneficial for treating cognitive deficits in a variety of disorders, particularly those that are associated with reduced glutamatergic signaling such as schizophrenia. In addition, LY404187 has been demonstrated to be efficacious in animal models of behavioral despair that possess considerable predictive validity for antidepressant activity. Although the therapeutic efficacy of AMPA receptor potentiators in these and other diseases will ultimately be determined in the clinic, evidence suggests that the benefit of these compounds will be mediated by multiple mechanisms of action. These mechanisms include direct enhancement of AMPA receptor function, secondary mobilization of intracellular signaling cascades, and prolonged modulation of gene expression.
LY404187是一种选择性、强效且具有中枢活性的AMPA受体正变构调节剂。与GluR1和GluR3 AMPA受体相比,LY404187优先作用于重组人同源性GluR2和GluR4。此外,LY404187对这些AMPA受体的翻转剪接变体的增强作用程度大于 flopped 剪接变体。在重组和天然AMPA受体中,LY404187的增强作用均表现出独特的时间依赖性增长,这似乎涉及对这些离子通道脱敏过程的抑制。LY404187已被证明在体外和体内均可增强谷氨酸能突触传递。突触活动的这种增强是由于AMPA受体功能的直接增强以及电压依赖性NMDA受体活性的间接募集。已知通过NMDA受体增强钙内流是启动突触功能长期改变(例如长期增强,LTP)的关键步骤。这些突触功能的改变可能是某些形式记忆编码的基础。与募集NMDA受体活性一致,LY404187已被证明可增强需要不同记忆过程的认知功能动物模型中的表现。这些数据表明,AMPA受体增强剂可能对治疗多种疾病中的认知缺陷具有治疗益处,特别是那些与谷氨酸能信号传导减少相关的疾病,如精神分裂症。此外,LY404187已被证明在具有相当抗抑郁活性预测效度的行为绝望动物模型中有效。尽管AMPA受体增强剂在这些和其他疾病中的治疗效果最终将在临床中确定,但有证据表明这些化合物的益处将由多种作用机制介导。这些机制包括直接增强AMPA受体功能、细胞内信号级联反应的二次动员以及基因表达的长期调节。